Loading
Life sciences · Journal article
International Journal of Advances in Medicine · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Globally, ovarian cancer (OC) is the eighth most common cancer among women, accounting for an estimated 3.7% of all cases and 4.7% of cancer-related deaths. Approximately 20-25% of OC cases harbour germline BRCA1/2 mutations, while homologous recombination deficiency (HRD) has emerged as an important therapeutic biomarker. Poly (ADP-ribose) polymerase (PARP) inhibitors, such as Olaparib, have demonstrated significant clinical benefit as maintenance therapy in patients with BRCA-mutated or HRD-positive OC. However, real-world Indian data on the clinical and molecular characteristics of patients receiving Olaparib remain limited. The objective of the study was to evaluate the clinical, molecular, and treatment profile of OC patients receiving Olaparib maintenance therapy. Methods: This ambispective, cross-sectional, multicentre, non-interventional, real-world evidence study aims to enrol 250 Indian OC patients initiated on Olaparib maintenance therapy. Data will be captured electronically at a baseline visit using an electronic data capture (EDC) system. Variables include demographics, comorbidities, family cancer history, histopathology, surgical and treatment history, BRCA mutation and HRD status, CA-125 levels at diagnosis and prior to Olaparib initiation, and details of maintenance therapy. Conclusions: OC-REAL India study will provide real-world insights into Indian OC patients on Olaparib, including demographics, pathology, and BRCA/HRD mutation prevalence. Findings aim to support personalized treatment and improve clinical outcomes. As this is an ongoing study, the results are expected to be published after completion of the study. Trial registration: The study was registered with the Clinical Trials Registry-India (CTRI; Registration No. CTRI/2025/08/092561)